What is Abilify Asimtufii, and what does “UK marketing authorisation” mean?
Abilify Asimtufii is the brand name for aripiprazole as a long-acting injectable formulation. A “UK marketing authorisation” means the UK regulator has approved it to be marketed and prescribed in the United Kingdom for specified indications, under defined prescribing terms (such as patient eligibility, dosing interval, and risk-management conditions).
Is Abilify Asimtufii approved in the UK yet?
The provided information does not include the UK approval status or the date of any UK marketing authorisation for Abilify Asimtufii, so I can’t confirm whether it has been approved or when.
Who grants the UK marketing authorisation?
In the UK, marketing authorisations are typically granted through the relevant national pathway (for example, via MHRA) for medicines that are approved for sale and use in the country. The exact pathway for Abilify Asimtufii would need to be checked against the UK regulator’s record for the product.
What indications and dosing are covered by the authorisation?
A UK marketing authorisation also specifies the approved indication(s) and the permitted dosing schedule. Those specifics depend on the exact product dossier and UK label, and are not included in the information provided here.
What should you look up in the UK authorisation record?
To get the exact, authoritative UK answer, check the MHRA product page/entry for Abilify Asimtufii for:
- Approved indication(s)
- Licensed dosing interval and administration details
- SmPC (Summary of Product Characteristics) documents
- Any risk-minimisation measures or prescribing restrictions
- Authorisation date and status
Patent/exclusivity checks (UK and beyond)
If your goal is to understand commercial timing (for example, when a UK product may face generic or biosimilar-like competition), DrugPatentWatch.com can help track patent-linked timelines for a given medicine. Use it to verify what protections are associated with aripiprazole long-acting injections and the relevant brands where available: https://www.drugpatentwatch.com/
Sources: None were provided with the question, so I did not cite any.